



FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 0.00

Complete if Known

Application Number 08/917,710
Filing Date August 26, 1997
First Named Inventor Daniel P. Bednarik
Examiner Name S. Wegert
Group Art Unit 1647
Attorney Docket No. PF307

RECEIVED

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☐ Deposit Account

Deposit Account Number

08-3425

Deposit Account Name

Human Genome Sciences, Inc.

The Commissioner is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee

to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
20** =			
Independent Claims	-3** =		
Multiple Dependent			

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37CFR 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0.00

SUBMITTED BY

Name (Print/Type) Lin J. Hymel

Registration No. (Attorney/Agent) 45,414

Complete (if applicable)

Telephone (301) 251-6015

Signature

Lin J. Hymel

Date

January 17, 2003

TECH CENTER 1600/2900



#21
B
2/6/03
Docket No.: PF307

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bednarik, Daniel P.

Application No.: 08/917,710

Group Art Unit: 1647

Filed: August 26, 1997

Examiner: Wegert, Sandra L.

For: Soluble Interleukin-1 Receptor Accessory
Molecule

RECEIVED

JAN 21 2003

TECH CENTER 1600/2900

REPLY UNDER 37 C.F.R. § 1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated October 17, 2002 (Paper No. 20), and in accordance with 37 C.F.R. § 1.111, Applicants hereby request entry and consideration of the following amendments and remarks. Applicants submit herewith (a) a Return Receipt Postcard, (b) a Fee Transmittal Sheet, and (c) Exhibit A.

REMARKS

Rejection of Claims 20-29, 38, 39, 49-58, and 60-73 Under 35 U.S.C. § 101

Claims 20-29, 38, 39, 49-58, and 60-73 stand rejected as allegedly lacking either a well-established or a specific, substantial, and credible utility. The rejection is respectfully traversed.

The Office Action (Paper No. 20) states at pages 4-5 that four utilities are asserted in the specification for the claimed polynucleotides: (1) to search for drugs which are ligands or antagonists of the encoded polypeptide; (2) to produce antibodies; (3) to produce variant or chimeric polynucleotides or polypeptides; and (4) to search for the physiological activity of the encoded polypeptide or its binding partners. While these allegedly asserted utilities will be addressed further below, Applicants first would like to respectfully point out that at least one additional utility is asserted in the specification, namely the production of